Investment
Features
FeesSafety
Academy
More
Pluang+

Compare e l f Beauty Inc (ELF) vs Eli Lilly And Co (LLY) Price & Performance

e l f Beauty IncTrade
Eli Lilly And CoTrade

Price performance (Past 24H)

Key statistics

e l f Beauty Inc vs Eli Lilly And Co — how do they compare? e l f Beauty Inc trades at $94.66 (market cap $5.62B), while Eli Lilly And Co trades at $1,216.2 (market cap $1.10T). The key difference: Eli Lilly And Co is far larger — about 195.7× e l f Beauty Inc's market cap, and Eli Lilly And Co pays a 0.56% dividend while e l f Beauty Inc pays none. Which is the better fit depends on your goals.

ELFLLY
Market Cap
$5.62B$1.10T
Sector
TechnologyHealth
52-Week High
$146.67$1.24K
52-Week Low
$49.57$635.22
Enterprise Value
$6.20B$1.14T
Dividend Yield
0.56%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

e l f Beauty Inc

ELF trades at $98.49, up 6.69% in 24 hours, near its 52-week high. The stock exhibits a bullish technical trend with strong support at $93 and resistance at $101. Recent Q2 2026 earnings beat expectations with EPS of $1.75 versus $0.71 expected, driven by 36% revenue growth and the Rhode acquisition. The company raised fiscal 2027 guidance, reflecting robust demand and international expansion.

Outlook remains positive due to consistent sales growth and strategic initiatives, but risks include high valuation (P/E 97.18) and reliance on acquisitions for growth. The stock offers growth potential but faces margin pressure from increased investments and competitive dynamics in the beauty sector.

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,185.71, down 0.59% on the day, with a bullish technical signal from moving averages and strong fundamental momentum. The company reported Q2 2026 revenue growth of 48% to $23 billion, beating estimates, driven by demand for Mounjaro and Zepbound. Valuation ratios like P/E of 39.8 and P/S of 13.34 reflect high growth expectations, while profitability remains robust with a net income margin of 33.53%.

Outlook is positive due to pipeline advancements like retatrutide and raised 2026 guidance, but risks include competitive pressures and regulatory scrutiny. Analysts are bullish with a consensus price target of $1,380, citing sustained double-digit growth and market leadership in weight-loss drugs as key drivers for upside.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About e l f Beauty Inc

e.l.f. Beauty is a leading cosmetics company offering high-quality, 100% vegan, and cruelty-free products. It is known for its affordable and prestige-quality makeup and skincare items for a diverse global audience.

Read more on ELF

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY